On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims stock crashed late Monday after the obesity kingpin lagged Wall Street's second-quarter sales forecasts, though profit ...

Q2 2025 Management View Andrew Dudum, CEO, highlighted the platform’s rapid growth, noting, “At the end of the second quarter, we were serving over 2.4 million subscribers on our platform with nearly ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

We recently published 10 Big Names Bleed Double Digits. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Hims & Hers Health, Inc. HIMS stock is trading lower Tuesday after the company reported a second-quarter sales miss on Monday ...

Find the latest Andrew Dudum news from Fast company. See related business and technology articles, photos, slideshows and videos.

Selling rock singles, saving Darfur Established musician and Wharton frosh beats out pro acts to headline campus benefit concert By Priyanka Dev 11/19/07 5:00am Andrew Dudum and his guitar While other ...